There has been an extensive search for developing medications which can be used to alleviate endometriosis-associated symptoms. Also, an already established medication, a new GnRH antagonist, elagolix, is in development. Its nonpeptide structure, allows it to be administered orally, which is its novelty to compared to other GnRH antagonists.

Many Phase I, II and III clinical trials were analyzed, through which the safety and efficacy of this new medication were evaluated.

According to the opinion of the researcher, as several medications have been put on the market, which gained popularity for the alleviation of endometriosis-associated symptoms. Elagolix has an advantage over established GnRH agonists, in that it does not lead to a ‘flare-up’ effect, it too, takes a toll on bone mineral density. However, studies have shown that this new oral GnRH antagonist is well tolerated, and have ‘mild or moderate’ the side effects. But there is a need for further studies in order to examine whether elagolix can compete with or even surpass established gold-standard medical treatments in this field, that directly compare elagolix to said treatments.